XOMA (NASDAQ:XOMA) Stock Rating Upgraded by TheStreet


Share on StockTwits

XOMA (NASDAQ:XOMA) was upgraded by TheStreet from a “d” rating to a “c” rating in a report issued on Tuesday, TheStreetRatingsTable reports.

Several other equities analysts also recently issued reports on the stock. Zacks Investment Research raised shares of XOMA from a “sell” rating to a “hold” rating in a report on Tuesday, March 16th. HC Wainwright boosted their price target on shares of XOMA from $30.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, January 19th.

XOMA stock opened at $38.60 on Tuesday. The company has a market cap of $434.37 million, a PE ratio of -34.77 and a beta of 1.26. The company has a fifty day moving average price of $37.85 and a two-hundred day moving average price of $33.85. The company has a debt-to-equity ratio of 0.61, a current ratio of 4.63 and a quick ratio of 4.63. XOMA has a 12 month low of $15.48 and a 12 month high of $46.32.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Tuesday, March 9th. The biotechnology company reported $1.32 EPS for the quarter, missing analysts’ consensus estimates of $2.00 by ($0.68). The business had revenue of $27.58 million during the quarter, compared to analyst estimates of $12.20 million. XOMA had a negative return on equity of 28.83% and a negative net margin of 102.23%. Equities research analysts anticipate that XOMA will post -1.34 earnings per share for the current year.

In related news, Director Bvf Partners L. P/Il sold 569,797 shares of XOMA stock in a transaction dated Wednesday, March 31st. The shares were sold at an average price of $38.36, for a total transaction of $21,857,412.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 9.89% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in XOMA by 6.0% in the fourth quarter. BlackRock Inc. now owns 477,053 shares of the biotechnology company’s stock worth $21,053,000 after acquiring an additional 26,836 shares in the last quarter. Cannell Capital LLC bought a new stake in XOMA in the fourth quarter worth about $506,000. Nuveen Asset Management LLC raised its position in XOMA by 82.5% in the fourth quarter. Nuveen Asset Management LLC now owns 21,915 shares of the biotechnology company’s stock worth $967,000 after acquiring an additional 9,908 shares in the last quarter. Infrastructure Capital Advisors LLC bought a new stake in XOMA in the fourth quarter worth about $210,000. Finally, Rhumbline Advisers bought a new stake in XOMA in the fourth quarter worth about $243,000. Institutional investors and hedge funds own 57.21% of the company’s stock.

About XOMA

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

See Also: How much money do you need to begin day trading?

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.